Navigation Links
Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Date:12/31/2007

FRAZER, Pa., Dec. 31 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of TREANDA(R) (bendamustine HCl) for Injection for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) who have progressed during or following treatment with rituximab or a rituximab-containing regimen. According to the National Cancer Institute, an estimated 30,000 people in the United States will be diagnosed in 2007 with indolent NHL, a serious and slow growing cancer of the lymphatic system that is difficult to treat because patients are prone to relapse after treatment.

"TREANDA is the lead product in our oncology pipeline and with this second NDA submission for the product in 2007 we have achieved a significant milestone for our business," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "The clinical data supporting this submission highlight the potential of TREANDA to make a meaningful difference for patients with indolent NHL who have relapsed during or following treatment with rituximab."

The TREANDA NDA for relapsed indolent NHL is supported by three studies in patients with NHL, including one in combination with rituximab. In these studies, patients treated with TREANDA had a high rate of response and a manageable and tolerable side effect profile, with adverse events similar to those observed with other chemotherapy agents.

About TREANDA

TREANDA is a novel chemotherapeutic agent, a hybrid of a purine analog and an alkylator. Preclinical data demonstrate that TREANDA acts in two distinct ways to kill cancer cells. TREANDA damages the DNA in cancer cells, which leads to cell death by a process known as apoptosis (programmed cell death) as well as by an alternate cell death (non-apoptotic) pathway known as mitotic catastrophe (a disruption of no
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
9. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
10. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
11. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Miami, FL (PRWEB) May 23, 2013 ... made trips to supermarkets to search for the ... grocery store aisles. Results from a year long study ... bacteria level in foods, specifically meats, over previous years. ... explains how the growth of antibiotic resistant bacteria in ...
(Date:5/23/2013)... Mass. , May 23, 2013 Pressure ... announced that the Company will host a teleconference to ... provide a business update. The teleconference information is provided ... 11:00 a.m. Eastern Daylight Time (EDT) Dial-in: ... ); (302) 607-2001 (Int,l) Passcode: VS22823 For ...
(Date:5/23/2013)... 2013 SynCardia Systems, Inc. ( http://www.syncardia.com ... Health Canada and CE (Europe) approved Total Artificial Heart, ... which boasts more than 380,000 visitors annually, is featuring ... by the Freedom® portable driver as part of its ... exhibitions of its kind. , “BodyWorks combines the ...
(Date:5/23/2013)... 2013 Watlow®, an industry leader ... systems, recently introduced its new catalog, Watlow® Heating ... in designing and manufacturing industrial heaters, Watlow provides ... serve diverse customer needs. , A description of ... beginning of the book. These options allow high ...
Breaking Biology Technology:Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3Watlow Introduces Its New Industrial Heater Catalog 2
... focused on commercialization of ColonSentry(TM); Asian resources ... - TORONTO, Nov. 12 /PRNewswire-FirstCall/ - GeneNews ... biomarker tests for the early,detection of diseases and ... a strategic restructuring of its North American and,Asian ...
... ... Association ... http://www.nicox.com , SOPHIA ANTIPOLIS, France, November 12 NicOx,S.A. (Euronext Paris: COX) today ... (ABPM) study for,naproxcinod was presented yesterday at the American Heart Association,Scientific Sessions 2008, in ...
... Sanofi Pasteur and Chumakov Institute Russian Academy Medical Sciences, ... Russia ... National "Project Health", PARIS, November 12 ... that Russia has,chosen inactivated polio vaccine (IPV) from Sanofi Pasteur ...
Cached Biology Technology:GeneNews restructures operations 2GeneNews restructures operations 3NicOx' Naproxcinod Shows Highly Significant Reduction in Daytime Blood Pressure Versus Naproxen 2NicOx' Naproxcinod Shows Highly Significant Reduction in Daytime Blood Pressure Versus Naproxen 3Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 2Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 3Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 4Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 5Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 6
(Date:5/21/2013)... a whale entangled in fishing gear, scientists showed for ... diving and swimming behavior. The monitoring revealed how fishing ... their energy as they drag gear for months or ... The scientists in this entanglement response suction-cupped a cellphone-size ... Atlantic right whale called Eg 3911. The Dtag, developed ...
(Date:5/21/2013)... class of pharmaceuticals can both prevent and treat Alzheimer,s ... "TSPO ligands," are currently used for certain types of ... ligand in young adult mice when pathology was at ... was quite severe," said lead researcher Christian Pike of ... measures of pathology and improved behavior at both ages." ...
(Date:5/21/2013)... pharmacies and health stores, phosphatidylserine is a natural ... Proven to improve cognition and slow memory loss, ... memory impairment. Now a team headed by Prof. ... Aviv University,s Department of Human Molecular Genetics ... the functioning of genes involved in degenerative brain ...
Breaking Biology News(10 mins):Study reveals how fishing gear can cause slow death of whales 2Study reveals how fishing gear can cause slow death of whales 3Drugs found to both prevent and treat Alzheimer's disease in mice 2Common food supplement fights degenerative brain disorders 2
... Kingston, ON A new approach to tracking ... more light on the potentially endangered Arctic animal and ... Integrating the traditional knowledge of Inuit hunters with state-of-the-art ... Peter V.C. de Groot and Peter Boag, is cheaper ...
... CORVALLIS, Ore. Researchers at Oregon State University recently completed ... toxicology, and the findings challenge some basic concepts about how ... considered safe. The study found that acceptable levels of ... higher than is currently believed. It also indicates that for ...
... SIB Swiss Institute of Bioinformatics and the Biozentrum of ... Biology Conference "Molecular Evolution", opened today at the Congress ... 200th birthday of Charles Darwin and the 150th anniversary ... Origin of the Species". Invited speakers include leading ...
Cached Biology News:New tracking approach will help protect polar bears 2Improved method developed to test carcinogen risk 2Improved method developed to test carcinogen risk 37th annual [BC]2 Basel Computational Biology Conference 'Molecular Evolution' June 18-19, 2009 27th annual [BC]2 Basel Computational Biology Conference 'Molecular Evolution' June 18-19, 2009 3
... derived from Paraffin embedded tissue blocks, which ... to ensure the highest quality. Tissues of ... block, sectioned at a thickness of 5 ... are large (3-5mm in diameter) in comparison ...
... , CapSure HS and CapSure Macro LCM ... of populations of pure cells from tissue ... Microdissection., Ensure the Integrity of Microdissected ... CapSure LCM Caps have a patented transfer ...
... Precision-designed for Optimal Microdissection , ... enable the precise and rapid extraction of ... and cytology samples with Laser Capture Microdissection., ... for Downstream Molecular Analysis , All CapSure ...
... PCR detector is an optical unit that ... Engine or Dyad Disciple gradient-capable thermal cycler ... scanning photonics shuttle that contains four LEDs ... 555-585 nm, 620-650 nm) and two filtered ...
Biology Products: